Literature DB >> 17852872

Barrett's oesophagus: intestinal metaplasia is not essential for cancer risk.

Clive J Kelty1, Martin D Gough, Quintin Van Wyk, Timothy J Stephenson, Roger Ackroyd.   

Abstract

OBJECTIVE: Barrett's oesophagus is the main identifiable risk factor for oesophageal adenocarcinoma. It has been suggested that only patients with intestinal metaplasia are at risk of cancer, but the British Society of Gastroenterology (BSG) guidelines suggest that glandular mucosa is all that is needed. The aim of this study was to quantify the risk of adenocarcinoma in columnar-lined lower oesophagus, with or without specialized intestinal metaplasia.
MATERIAL AND METHODS: All patients who had endoscopic biopsies of the lower oesophagus between 1980 and 1994 in a single-centre teaching hospital were included in the study. All histological specimens were re-examined and reported according to whether they contained columnar epithelial-lined lower oesophagus, glandular mucosa, with or without intestinal metaplasia. The primary outcome measure was the development of adenocarcinoma.
RESULTS: In total, 712 patients were identified. Of these, 379 (55.1%) were found to have specialized intestinal metaplasia (SIM), and the remaining 309 (44.9%, p = NS) were reported as having glandular mucosa (GM). The median follow-up for patients was 12 years (range 8-20 years). Twenty-eight patients went on to develop adenocarcinoma (4.1%) during the follow-up period - 17 in the SIM group (4.5%) and 11 in the GM group (3.6%, p =NS). The oesophageal malignancy rate was 0.34% per year (SIM 0.37%, GM 0.30%; p =NS).
CONCLUSIONS: Patients who have glandular mucosa on biopsy without intestinal metaplasia have a similar cancer risk to those with specialized intestinal metaplasia.

Entities:  

Mesh:

Year:  2007        PMID: 17852872     DOI: 10.1080/00365520701420735

Source DB:  PubMed          Journal:  Scand J Gastroenterol        ISSN: 0036-5521            Impact factor:   2.423


  54 in total

1.  Bile acid and inflammation activate gastric cardia stem cells in a mouse model of Barrett-like metaplasia.

Authors:  Michael Quante; Govind Bhagat; Julian A Abrams; Frederic Marache; Pamela Good; Michele D Lee; Yoomi Lee; Richard Friedman; Samuel Asfaha; Zinaida Dubeykovskaya; Umar Mahmood; Jose-Luiz Figueiredo; Jan Kitajewski; Carrie Shawber; Charles J Lightdale; Anil K Rustgi; Timothy C Wang
Journal:  Cancer Cell       Date:  2012-01-17       Impact factor: 31.743

Review 2.  Barrett esophagus: an update.

Authors:  Rami J Badreddine; Kenneth K Wang
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2010-06-01       Impact factor: 46.802

Review 3.  Barrett's esophagus: Clinical issues.

Authors:  Stuart Jon Spechler
Journal:  Gastrointest Endosc Clin N Am       Date:  2011-01

Review 4.  Barrett's Esophagus: A Comprehensive and Contemporary Review for Pathologists.

Authors:  Bita V Naini; Rhonda F Souza; Robert D Odze
Journal:  Am J Surg Pathol       Date:  2016-05       Impact factor: 6.394

5.  Consensus statements for management of Barrett's dysplasia and early-stage esophageal adenocarcinoma, based on a Delphi process.

Authors:  Cathy Bennett; Nimish Vakil; Jacques Bergman; Rebecca Harrison; Robert Odze; Michael Vieth; Scott Sanders; Laura Gay; Oliver Pech; Gaius Longcroft-Wheaton; Yvonne Romero; John Inadomi; Jan Tack; Douglas A Corley; Hendrik Manner; Susi Green; David Al Dulaimi; Haythem Ali; Bill Allum; Mark Anderson; Howard Curtis; Gary Falk; M Brian Fennerty; Grant Fullarton; Kausilia Krishnadath; Stephen J Meltzer; David Armstrong; Robert Ganz; Gianpaolo Cengia; James J Going; John Goldblum; Charles Gordon; Heike Grabsch; Chris Haigh; Michio Hongo; David Johnston; Ricky Forbes-Young; Elaine Kay; Philip Kaye; Toni Lerut; Laurence B Lovat; Lars Lundell; Philip Mairs; Tadakuza Shimoda; Stuart Spechler; Stephen Sontag; Peter Malfertheiner; Iain Murray; Manoj Nanji; David Poller; Krish Ragunath; Jaroslaw Regula; Renzo Cestari; Neil Shepherd; Rajvinder Singh; Hubert J Stein; Nicholas J Talley; Jean-Paul Galmiche; Tony C K Tham; Peter Watson; Lisa Yerian; Massimo Rugge; Thomas W Rice; John Hart; Stuart Gittens; David Hewin; Juergen Hochberger; Peter Kahrilas; Sean Preston; Richard Sampliner; Prateek Sharma; Robert Stuart; Kenneth Wang; Irving Waxman; Chris Abley; Duncan Loft; Ian Penman; Nicholas J Shaheen; Amitabh Chak; Gareth Davies; Lorna Dunn; Yngve Falck-Ytter; John Decaestecker; Pradeep Bhandari; Christian Ell; S Michael Griffin; Stephen Attwood; Hugh Barr; John Allen; Mark K Ferguson; Paul Moayyedi; Janusz A Z Jankowski
Journal:  Gastroenterology       Date:  2012-04-24       Impact factor: 22.682

6.  Metaplastic esophageal columnar epithelium without goblet cells shows DNA content abnormalities similar to goblet cell-containing epithelium.

Authors:  Weitian Liu; Hejin Hahn; Robert D Odze; Raj K Goyal
Journal:  Am J Gastroenterol       Date:  2009-03-17       Impact factor: 10.864

Review 7.  [Update on Barrett esophagus and Barrett carcinoma].

Authors:  M Werner; S Laßmann
Journal:  Pathologe       Date:  2012-11       Impact factor: 1.011

8.  Cdx2 expression and its promoter methylation during metaplasia-dysplasia-carcinoma sequence in Barrett's esophagus.

Authors:  Kenji Makita; Riko Kitazawa; Shuho Semba; Koto Fujiishi; Miku Nakagawa; Ryuma Haraguchi; Sohei Kitazawa
Journal:  World J Gastroenterol       Date:  2013-01-28       Impact factor: 5.742

Review 9.  History, molecular mechanisms, and endoscopic treatment of Barrett's esophagus.

Authors:  Stuart Jon Spechler; Rebecca C Fitzgerald; Ganapathy A Prasad; Kenneth K Wang
Journal:  Gastroenterology       Date:  2010-01-18       Impact factor: 22.682

10.  Barrett's esophagus: is the goblet half empty?

Authors:  Stuart Jon Spechler
Journal:  Clin Gastroenterol Hepatol       Date:  2012-08-17       Impact factor: 11.382

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.